

Outpatient Ambulatory Health Services (OAHS)

SITE:		CHART #:	
REVIEWER:		DATE:	

PROGRAM MONITORING	Compliant	Non-Compliant	Not Applicable	Not Reviewed
Staff Verification Individual clinicians shall have documented unconditional licensure/certification in his/her particular area of practice				
Supervision Service providers shall employ clinical staff who is knowledgeable and experienced regarding their area of clinical practice as well as in the area of HIV/AIDS clinical practice. All staff without direct experience with HIV/AIDS shall be supervised by one who has such experience.				
CEU/CME Staff participating in the direct provision of services to patients must satisfactorily complete all appropriate CEUs based on individual licensure requirements.				
Agency Verification/Licensure: Facility licensure current where applicable				
Quality Improvement Plan Service providers shall have an established quality assurance/performance improvement plan.				
Quality Improvement Projects Agency has 2 QI Projects in Process				
CHART MONITORING	Compliant	Non-Compliant	Not Applicable	Not Reviewed

INITIAL MEDICAL EVALUATION/ASSESSMENT

NEWLY DIAGNOSED NEW TO CARE					
NEWLY DIAGNOSED NEW TO CARE	Linkage to Care Percentage of patients who attended a routine HIV medical care visit within 3 months of HIV diagnosis. (HRSA HAB measure)				
	Comprehensive HIV related History Percentage of new patients with a documented comprehensive HIV related history that is inclusive of all components listed in the OAHS Standard as referenced in the HHS guidelines.				
	Physical Exam Percentage of new patients with a documented annual physical examination including complete review of systems.				
	Initial Oral Cavity Exam documented				
	Oral Health Examination Documentation that an oral examination by a dentist was completed at least once during the measurement year (based on self report or other documentation). (HRSA HAB Measure)				

INITIAL LABORATORY TESTS, AS CLINICALLY INDICATED BY LICENSED PROVIDER

AGNOSED TO CARE					
AGNOSED TO CARE	HIV Antibody, if not documented previously				
	CD4 Count and/or CD4 Percentage				
	Quantitative Plasma HIV RNA (HIV Viral Load): Percentage of patients with documented HIV-RNA viral load. (HRSA HAB Measure)				
	Drug Resistance Testing (genotype, phenotype) - recommended at time of initial care: Percentage of new patients with documented drug resistance testing, as applicable.				
	Co-receptor Tropism Test (if considering use of CCR5 co-receptor antagonist or for patients who exhibit virologic failure on a CCR5 antagonist)				
	HLA-B*5701 testing (only before initiating abacavir-containing regimen per guidelines)				
	Complete Blood Count (CBC) with Differential and Platelets				
	Chemistry Profile: Electrolytes, Creatinine, Blood Urea Nitrogen (BUN)				
	Liver Transaminases, Bilirubin (Total and Direct)				
	Urinalysis with Urine Protein and Creatinine				
	Quantitative HCV RNA viral load testing (for Hepatitis C positive patients who are candidates for treatment)				
Hepatitis A total antibody, Hepatitis B surface antigen, core Ab, and surface antibody & Hepatitis C antibody screens at initial intake (providers should screen all HIV-infected patients for anti-HCV antibodies at baseline)					

NEWLY DL
NEW TC

Hepatitis B: Percentage of new patients, regardless of age, for whom Hepatitis B screening was performed at least once since the diagnosis of HIV/AIDS or for whom there is documented infection or immunity. (HRSA HAB Measure)				
Hepatitis C: Percentage of new patients for whom Hepatitis C (HCV) screening was performed at least once since the diagnosis of HIV. (HRSA HAB Measure)				
Lipid Profile (Total Cholesterol, LDL, HDL, Triglycerides); Fasting				
Glucose (preferably fasting) or hemoglobin A1C				
Pregnancy Test (for female clients of childbearing potential)				
Serum VDRL or RPR or treponemal antibody (Syphilis Screening): Percentage of new adult patients with a diagnosis of HIV who had a test for syphilis performed within the measurement year. (HRSA HAB Measure)				
Gonorrhea (GC) Testing: Percentage of new patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for gonorrhea within the measurement year. (HRSA HAB Measure)				
Chlamydia (CT) Testing: Percentage of new patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for chlamydia within the measurement year. (HRSA HAB Measure)				
Toxoplasma gondii IgG				
Trichomoniasis Testing				

OTHER DIAGNOSTIC TESTING

Percentage of new patients with documented initial laboratory tests completed according to the OAHS Standard and HHS Treatment Guidelines				
--	--	--	--	--

INITIAL SCREENINGS/ASSESSMENTS

NEWLY DIAGNOSED
NEW TO CARE

Percentage of new patients with documented chest x-ray completed if pulmonary symptoms were present or LTBI test was positive.				
Percentage of new patients with documented initial medical screenings and assessments as indicated in the OAHS Standard and in accordance with HHS guidelines				
Child Abuse Assessment: Percentage of new patients, if applicable, with completed child abuse assessment (completed if patient aged 14 years and younger)..				
Cervical Cancer Screen: Percentage of new female patients with a diagnosis of HIV who were screened for cervical cancer in the last three years. (HRSA HAB Measure)				
Cervical Cancer Screen for HIV-infected Women Aged <30 years: If known to be HIV-infected or newly diagnosed with HIV, and sexually active, screen within 1 year of onset of sexual activity regardless of mode of HIV infection				
Cervical Cancer Screen Women Aged 21-29: Initial Pap test following initial diagnosis then every 12 months. If results of 3 consecutive Pap tests are normal, follow up Pap tests can be performed every 3 years.				
Cervical Cancer Screen Women Aged >30 Years: Pap test should be done at baseline and every 12 months. If results of 3 consecutive Pap test are normal, follow-up Pap tests can be performed every 3 years.				
Pap Test and HPV Co-Testing: Pap test and HPV co-testing should be done at baseline.				
Mental Health Assessment: Percentage of new patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen. (HRSA HAB Measure)				
Substance Use and Abuse Screening: Percentage of new patients with diagnosis of HIV who have been screened for substance use (alcohol & drugs) in the measurement year. (HRSA HAB Measure)				

Psychosocial Assessment: Percentage of new patients with documented initial psychosocial assessment to include domestic violence and housing status.				
Tuberculosis (TB) Screening: Percentage of new patients aged 3 months and older with a diagnosis of HIV/AIDS, for whom there was documentation that a tuberculosis (TB) screening test was performed and results interpreted (for TB skin tests) at least once since the diagnosis of HIV infection. (HRSA HAB Measure)				
Tobacco Use Screening: Percentage of new patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user. (HRSA HAB Measure)				

SECTION 2: Chart Review

****Review for all patients in care on (1) year or more with same medical provider ****

ONGOING MEDICAL EVALUATION/ASSESSMENT

Existing Patients/Ongoing Medical Care	Medical Evaluation/Assessment: Percentage of existing patients (return to care and those in current medical care for more than one year) with a documented comprehensive assessment/evaluation completed by the MD, NP, CNS, or PA within 15 business days of initial contact with patient in accordance with professional and established HIV practice guidelines.				
	Comprehensive HIV related History: Percentage of existing patients with a documented comprehensive HIV related history that is inclusive of all components listed in the OAHs Standard as referenced in the HHS guidelines.				
	Physical Exam: Percentage of existing patients with a documented annual physical examination including complete review of systems conducted during the comprehensive medical history.				
	Oral Cavity Exam documented				
	Oral Health Examination Documentation that an oral examination by a dentist was completed at least once during the measurement year (based on self report or other documentation). (HRSA HAB Measure)				

ONGOING MEDICAL CARE - LABORATORY TESTS, AS CLINICALLY INDICATED BY LICENSED PROVIDER

Existing Patients/Ongoing Medical Care	HIV Antibody, if not documented previously				
	CD4 Count and/or CD4 Percentage				
	Quantitative Plasma HIV RNA (HIV Viral Load): Percentage of patients with documented HIV-RNA viral load. (HRSA HAB Measure)				
	Co-receptor Tropism Test (if considering use of CCR5 co-receptor antagonist or for patients who exhibit virologic failure on a CCR5 antagonist)				
	HLA-B*5701 testing (only before initiating abacavir-containing regimen per guidelines)				
	Complete Blood Count (CBC) with Differential and Platelets				
	Chemistry Profile: Electrolytes, Creatinine, Blood Urea Nitrogen (BUN)				
	Liver Transaminases, Bilirubin (Total and Direct)				
	Urinalysis with Urine Protein and Creatinine				
	Quantitative HCV RNA viral load testing (for Hepatitis C positive patients who are candidates for treatment)				
	Lipid Profile (Total Cholesterol, LDL, HDL, Triglycerides); Fasting				
	Glucose (preferably fasting) or hemoglobin A1C				
Pregnancy Test (for female clients of childbearing potential)					

Exit	Serum VDRL or RPR or treponemal antibody (Syphilis Screening): Percentage of new adult patients with a diagnosis of HIV who had a test for syphilis performed within the measurement year. (HRSA HAB Measure)				
	Gonorrhea (GC) Testing: Percentage of new patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for gonorrhea within the measurement year. (HRSA HAB Measure)				
	Chlamydia (CT) Testing: Percentage of new patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for chlamydia within the measurement year. (HRSA HAB Measure)				
	Toxoplasma gondii IgG				
	Trichomoniasis Testing				
OTHER DIAGNOSTIC TESTING					
	Percentage of existing patients with documented chest x-ray completed if pulmonary symptoms were present, after an initial positive Interferon Gamma Release Assay (IGRA), after initial positive TST, or annually if prior evidence of LTBI or pulmonary TB.				
FOLLOW-UP VISITS					
	Percentage of existing patients with documented initial medical screenings and assessments as indicated in the OAHs Standard and in accordance with HHS guidelines.				
	HIV Medical Visit Frequency: Percentage of patients, regardless of age, with a diagnosis of HIV who had at least one medical visit in each 6-month period of the 24-month measurement period with a minimum of 60 days between medical visits. (HRSA HAB Measure)				
	Gap in Medical Visits: Percentage of patients, regardless of age, with a diagnosis of HIV who did not have a medical visit in the last 6 months of the measurement year. (HRSA HAB Measure)				
	Viral Load Suppression: Percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year. (HRSA HAB Measure)				
	Cervical Cancer Screen: Percentage of new female patients with a diagnosis of HIV who were screened for cervical cancer in the last three years. (HRSA HAB Measure)				
	Cervical Cancer Screen for HIV-infected Women Aged <30 years: If known to be HIV-infected or newly diagnosed with HIV, and sexually active, screen within 1 year of onset of sexual activity regardless of mode of HIV infection				
	Cervical Cancer Screen Women Aged >30 Years: Pap test should be done at baseline and every 12 months. If results of 3 consecutive Pap test are normal, follow-up Pap tests can be performed every 3 years.				
	Pap Test and HPV Co-Testing: Pap test and HPV co-testing should be done at baseline.				
	Syphilis Screening: Percentage of existing adult patients with a diagnosis of HIV who had a test for syphilis performed within the measurement year. (HRSA HAB Measure)				
	Serologic Test for Syphilis: Percentage of existing patients with documented serologic test for syphilis performed. (HRSA HAB Measure)				
	Gonorrhea (GC) Testing: Percentage of existing patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for gonorrhea within the measurement year. (HRSA HAB Measure)				
	Chlamydia (CT) Testing: Percentage of existing patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for chlamydia within the measurement year. (HRSA HAB Measure)				

	Mental Health Assessment: Percentage of existing patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen. (HRSA HAB Measure)				
	Substance Use and Abuse Screening: Percentage of existing patients with diagnosis of HIV who have been screened for substance use (alcohol & drugs) in the measurement year. (HRSA HAB Measure)				
	Psychosocial Assessment: Percentage of existing patients with documented initial psychosocial assessment to include domestic violence and housing status.				
	Tuberculosis (TB) Screening: Percentage of existing patients aged 3 months and older with a diagnosis of HIV/AIDS, for whom there was documentation that a tuberculosis (TB) screening test was performed and results interpreted (for TB skin tests) at least once since the diagnosis of HIV infection. (HRSA HAB Measure)				
	Tobacco Use Screening: Percentage of existing patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user. (HRSA HAB Measure)				
	Hepatitis B Screen: Percentage of existing patients, regardless of age, for whom Hepatitis B screening was performed at least once since the diagnosis of HIV/AIDS or for whom there is documented infection or immunity. (HRSA HAB Measure)				
	Hepatitis C Screen: Percentage of existing patients for whom Hepatitis C (HCV) screening was performed at least once since the diagnosis of HIV. (HRSA HAB Measure)				
	Lipid Panel: Percentage of patients, regardless of age, with a diagnosis of HIV who were prescribed HIV antiretroviral therapy and who had a fasting lipid panel during the measurement year. (HRSA HAB Measure)				

SECTION 3: Chart Review

IMMUNIZATIONS

IMMUNIZATIONS	Tetanus, Diphtheria, and Pertussis current within 10 years, Td booster doses every 10 years thereafter, or documentation of refusal.				
	Documentation that pediatric patients had at least one dose of Measles, Mumps, Rubella (MMR) vaccine administered between 12-24 months of age, or documentation of refusal. (HRSA HAB measure for pediatrics)				
	Influenza vaccine given to patients aged 6 months or older between October 1st and March 31st of the measurement year, or report of previous receipt of an influenza immunization, or documentation of refusal. (HRSA HAB measure)				
	Pneumococcal vaccine ever given or documentation of refusal. (HRSA HAB measure).				
	Hepatitis B vaccine series completed or documentation of immunity, deferral, or refusal. (HRSA HAB measure)				
	Hepatitis A vaccine series completed or documentation of immunity, deferral, or refusal.				
	Varicella-Zoster (VZV), as medically indicated; Varicella titers at baseline, consider vaccination if negative titers and CD4 \geq 200				
	Zoster vaccine (shingles vaccine) consideration if age >50 and CD4 \geq 200.				
	HPV administered to patients between ages 9 and 26 years or documentation of immunity, deferral, or refusal.				
Meningococcal as medically indicated or documentation of refusal					

ANTIBIOTIC TREATMENT (RECOMMEND PROPHYLACTIC ANTIBIOTIC TREATMENT)

	MAC Prophylaxis: Percentage of patients who were prescribed antibiotic prophylaxis if CD4<50 (MAC) and/or if CD4<100 and toxoplasma IgG is positive.				
ANTIRETROVIRAL THERAPY & RECOMMENDATIONS FOR PREVENTION AND TREATMENT OF PNEUMOCYSTIS PNEUMONIA (PCP)					
	Percentage of patients, regardless of age, with a diagnosis of HIV are prescribed antiretroviral therapy for the treatment of HIV infection during the measurement year. (HRSA HAB Measure)				
	Patients aged 6 weeks or older with CD4 counts of less than 200 cells/μL or a CD4 percentage below 15% prescribed PCP or documentation of deferral or refusal. (HRSA HAB measure)				
DRUG RESISTENCE TESTING					
	Documented drug resistance testing was performed before initiation of HIV antiretroviral therapy if therapy started within the measurement year. (HRSA HAB measure)				
	Drug Resistance Testing Counseling and Education must be provided by the patient's medical practitioner, registered nurse and/or other appropriate licensed healthcare provider (if designated by the practitioner).				
HEALTH EDUCATION/RISK REDUCTION					
HEALTH EDUCATION/ RISK REDUCTION	HIV Risk Counseling: Percentage of patients with a diagnosis of HIV who received HIV risk counseling in the measurement year. (HRSA HAB Measure)				
	Documented counseling within the past 12 months regarding increased risk of transmitting HIV during HIV infection and safer sexual practices.				
	Documented counseling within the past 12 months about the risk of acquiring syphilis and other STIs from unprotected sexual contact, including all sites of possible transmission, such as anus, cervix, vagina, urethra, and oropharynx.				
	Documented counseling about family planning method appropriate to patient's status, as applicable.				
	Documented preconception counseling as appropriate.				
	Documented instruction regarding new medications/ treatments/ tests as appropriate.				
	Documented counseling regarding the importance of disclosure to partners.				
	Tobacco Cessation: Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user. (HRSA HAB Measure)				
TREATMENT ADHERENCE					
	Treatment Adherence Assessment Documented assessment for treatment adherence two or more times within the measurement year if patient on ARV				
	Adherence Counseling If patient on ARVs with documented adherence issue, received counseled for treatment adherence two or more times within the measurement year.				
REFERRALS					
	Referral for health maintenance Documented referral as clinically appropriate: <ul style="list-style-type: none"> • Cervical Cancer Screening - annually after 2 negative screens 6 months apart • Family Planning - annually • Colorectal cancer screening - every 10 years unless patient condition indicated more frequent • Breast Cancer screening - annually unless patient condition indicated different frequency Adherence Counseling If patient on ARVs with documented adherence issue, received counseled for treatment adherence two or more times within the measurement year.				

REFERRALS

Referral for Adherence Counseling Documented referral made to medical case management for medication adherence if appropriate.				
Referral for Mental Health/Substance Use Documented referral made to a mental health provider and/or substance use counselor if indicated.				
Referral for Oral Health Documented referral to dentist for Oral Health in medical chart or that patient is already seeing dentist (can be patient self report).				
Referral for Ophthalmic Documented referral if CD4 count was below 50.				
Referral for Treatment Suitability Newly diagnosed HIV+/HCV patients have referral for treatment suitability and/or documented evaluation.				
Referral for Child Abuse If suspected abuse is indicated; proper authorities contacted and documented in patient's file.				
Referral to Disease Intervention Specialist Documented referral to case management or DIS if patient is not attending appointments.				
Other Specialty Services Documented referral to specialty services as appropriate <ul style="list-style-type: none"> • AIDS Drug Assistance Program (ADAP) • Medication Assistance Programs • Medical care coordination • Medical specialties • Psychiatric and mental health services • Treatment education services • Substance use services • Partner counseling and referral • Medical Nutrition Therapy • HIV resources and support opportunities 				
Follow-up on Referrals Each referral has a progress note in the patients chart regarding attendance and outcomes.				
DOCUMENTATION IN PATIENTS' MEDICAL CHART				
Signed clinician entries.				
Flow sheet present and updated.				
Problem list present and updated.				
Medication list present and updated.				
DOCUMENTATION OF MISSED APPOINTMENTS AND EFFORTS TO BRING PATIENTS INTO CARE				
Documentation of a minimum of 3 different contacts (email, phone, mail, emergency contact, home visit by DIS) when patient has missed 3 scheduled appointments in 3-month period.				
Documentation of any specific barriers and efforts made to address missed appointments.				